Efficacy and safety of biological agents in adult-onset Still's disease

Scandinavian Journal of Rheumatology

Volumn 44, Issue 4, 2015, Pages 309-314

  Cavalli, G ^a   Franchini, S ^b   Aiello, P ^b   Guglielmi, B ^b   Berti, A ^a   Campochiaro, C ^a   Sabbadini, M G ^a   Baldissera, E ^b   Dagna, L ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB; BIOLOGICAL FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ADULT ONSET STILL DISEASE; AGED; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INJECTION SITE REACTION; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PRIORITY JOURNAL; TREATMENT OUTCOME; YOUNG ADULT; ADOLESCENT; ANTAGONISTS AND INHIBITORS; COHORT ANALYSIS; COMPARATIVE STUDY; LONGITUDINAL STUDY; RETROSPECTIVE STUDY; STILL'S DISEASE, ADULT-ONSET;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL FACTORS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84937798200     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2014.992949     Document Type: Article

References (16)

1. Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. Arthritis Rheum 2010;62:2530-5.
2. Al-Homood IA. Biologic treatments for adult-onset Still's disease. Rheumatology (Oxford) 2014;53:32-8.
3. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424-30.
4. Cush JJ, Medsger TA, Christy WC, Herbert DC, Cooperstein LA. Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum 1987;30:186-94.
5. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794-803.
6. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis S-NC. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 2007;66:842-3.
7. Nordström D, Knight A, Luukkainen R, van Vollenhoven R, Rantalaiho V, Kajalainen A, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol 2012;39:2008-11.
8. Rech J, Ronneberger M, Englbrecht M, Finzel S, Katzenbeisser J, Manger K, et al. Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis 2011;70:390-2.
9. Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005;64:262-6.
10. Puéchal X, DeBandt M, Berthelot J-M, Breban M, Dubost J-J, Fain O, et al. Tocilizumab in refractory adult Still's disease. Arthritis Care Res (Hoboken) 2011;63:155-9.
11. Kötter I, Wacker A, Koch S, Henes J, Richter C, Engel A, et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 2007;37:189-97.
12. Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67:302-8.
13. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and longterm follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res Ther 2011;13:R91.
14. Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, et al. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken) 2013;65:822-6.
15. Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002;46:1171-6.
16. Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol 2012;22:712-19.